Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS) issued its quarterly earnings data on Thursday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08), MarketWatch Earnings reports.

CRVS stock opened at $4.24 on Friday. The business’s fifty day moving average price is $3.60 and its 200 day moving average price is $3.54. Corvus Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $6.88. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.03.

In related news, major shareholder Holdings A/S Novo sold 1,538,062 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $5.31, for a total transaction of $8,167,109.22. Following the completion of the transaction, the insider now directly owns 2,130,938 shares in the company, valued at approximately $11,315,280.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 45.12% of the stock is currently owned by corporate insiders.

CRVS has been the subject of a number of research analyst reports. Zacks Investment Research cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 13th. Mizuho reaffirmed a “buy” rating and set a $7.00 target price on shares of Corvus Pharmaceuticals in a research note on Thursday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Corvus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $7.25.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

See Also: Hold Rating

Earnings History for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with's FREE daily email newsletter.